Matches in Nanopublications for { ?s ?p "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP133562.RAYO-MF0UIl9xSn7TLT6q5g308l6Ibc7fjXbvWMHuMcuU130_assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133562.RAYO-MF0UIl9xSn7TLT6q5g308l6Ibc7fjXbvWMHuMcuU130_provenance.
- NP133563.RATggQGVJ63BDDayjrErUuJPn_5lZXJo4iEhgJudwYatw130_assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133563.RATggQGVJ63BDDayjrErUuJPn_5lZXJo4iEhgJudwYatw130_provenance.
- NP133564.RAXCjAs6RgzielHzgSO0rI4fTaR3n1NvIqOSM4K9mKkVs130_assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133564.RAXCjAs6RgzielHzgSO0rI4fTaR3n1NvIqOSM4K9mKkVs130_provenance.
- NP184276.RABTfJxzRE0S9__ecw6FSGD23lIf5DdquUDFAUPhrf6ls130_assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184276.RABTfJxzRE0S9__ecw6FSGD23lIf5DdquUDFAUPhrf6ls130_provenance.
- NP184279.RAVKBjQpucq0bPKbfz81xKOVT0Kbc38X9PrmerLER_O8o130_assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184279.RAVKBjQpucq0bPKbfz81xKOVT0Kbc38X9PrmerLER_O8o130_provenance.
- NP184278.RAtGfW3npVSJE1fMSxP05fzHnxMl1pksKqYa8We_6XtM0130_assertion description "[Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184278.RAtGfW3npVSJE1fMSxP05fzHnxMl1pksKqYa8We_6XtM0130_provenance.